NSEI:WANBURY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally.


Snowflake Analysis

Good value with questionable track record.

Share Price & News

How has Wanbury's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: WANBURY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.8%

WANBURY

0.2%

IN Pharmaceuticals

1.2%

IN Market


1 Year Return

228.5%

WANBURY

49.6%

IN Pharmaceuticals

4.3%

IN Market

Return vs Industry: WANBURY exceeded the Indian Pharmaceuticals industry which returned 49.6% over the past year.

Return vs Market: WANBURY exceeded the Indian Market which returned 4.3% over the past year.


Shareholder returns

WANBURYIndustryMarket
7 Day9.8%0.2%1.2%
30 Day40.8%12.4%7.1%
90 Day125.8%23.7%23.6%
1 Year228.5%228.5%51.8%49.6%6.3%4.3%
3 Year6.7%6.7%36.2%32.2%4.2%-0.7%
5 Year-40.4%-40.4%-0.8%-4.4%34.4%24.4%

Price Volatility Vs. Market

How volatile is Wanbury's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Wanbury undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: WANBURY (₹41.55) is trading below our estimate of fair value (₹194.43)

Significantly Below Fair Value: WANBURY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: WANBURY is good value based on its PE Ratio (1.5x) compared to the IN Pharmaceuticals industry average (22.2x).

PE vs Market: WANBURY is good value based on its PE Ratio (1.5x) compared to the Indian market (14.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate WANBURY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: WANBURY has negative assets, so we can't compare its PB Ratio to the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is Wanbury forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wanbury has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Wanbury performed over the past 5 years?

-2.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: WANBURY has a large one-off gain of ₹826.4M impacting its March 31 2020 financial results.

Growing Profit Margin: WANBURY became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: WANBURY has become profitable over the past 5 years, growing earnings by -2.4% per year.

Accelerating Growth: WANBURY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: WANBURY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: WANBURY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Wanbury's financial position?


Financial Position Analysis

Short Term Liabilities: WANBURY has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: WANBURY has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: WANBURY has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: WANBURY's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: WANBURY's debt is well covered by operating cash flow (35.5%).

Interest Coverage: WANBURY's interest payments on its debt are not well covered by EBIT (0.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Wanbury current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate WANBURY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate WANBURY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if WANBURY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if WANBURY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: WANBURY is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of WANBURY's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Wanbury has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
K. Chandran
Vice Chairmanno datano datano data
Vinod Verma
Chief Financial Officer4.33yrs₹13.98mno data
Jitendra Gandhi
Compliance Officer & Company Secretary5.25yrs₹3.10mno data
Shireesh Ambhaikar
President of Operations - API Business2.92yrs₹12.17mno data
Nanasaheb Gunjal
Senior Vice President of QAno datano datano data

4.3yrs

Average Tenure

Experienced Management: WANBURY's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
K. Chandran
Vice Chairmanno datano datano data
S. Bhattacharya
Non-Executive Independent Director7.25yrs₹364.00kno data
Narinder Puri
Non-Executive Independent Director15.42yrs₹460.00kno data
Pallavi Shedge
Non-Executive Independent Woman Director1.5yrs₹100.00kno data

7.3yrs

Average Tenure

70yo

Average Age

Experienced Board: WANBURY's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.


Top Shareholders

Company Information

Wanbury Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Wanbury Limited
  • Ticker: WANBURY
  • Exchange: NSEI
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.026b
  • Shares outstanding: 25.00m
  • Website: https://www.wanbury.com

Number of Employees


Location

  • Wanbury Limited
  • BSEL Tech Park, B-Wing
  • 10th Floor
  • Navi Mumbai
  • Maharashtra
  • 400703
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524212BSE (Mumbai Stock Exchange)YesEquity SharesININRFeb 2005
WANBURYNSEI (National Stock Exchange of India)YesEquity SharesININRFeb 2005

Biography

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, heamatinics, anti- ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 07:58
End of Day Share Price2020/08/13 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.